News

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

Amid major national judicial and legislative deliberation on reproductive health care access, the Brigham and Women's and Harvard University expert joins to discuss the clinical matters of abortion.

These data further elucidate the relationship between mental health and diabetic retinopathy.

However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.

A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.

The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.

Expert gynecologist Dr. Deborah Bartz addresses the clinical implications of an abortion ban if Roe v. Wade is overturned.

New data from phase 3 of the ORCA-2 trial found that adults treated 3 times daily with cytisinicline were more inclined to quit smoking cigarettes.

The risk of cSCC was significantly higher in patients who received treatment for actinic keratosis.

New-onset diarrhea is common among inpatients and residents of long-term care facilities.

The Elevatum trial will assess the newly approved ophthalmic drug in patients from African American, Hispanic, Latin American, and Indigenous communities.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

The estimated median duration of ≥1 line gained was greater than 9 hours on both study day 1 and day 30 in patients with presbyopia treated with the study agent.

A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.

Data suggest baseline vision was a key predictor of poor response at Week 24 in patients with macular edema secondary to central retinal vein occlusion.

New research found veterans with diabetes who took L-DOPA and dopamine agonists showed delayed onset of vascular pathology associated with DR.

A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.

A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.

An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

Data show Black individuals had a 1.41 times higher odds of having type 2 diabetic retinopathy when compared to white individuals.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.

Investigators suggested future research was needed to identify elements of learning environments that contribute to burnout among sexual minority students.

The most common diagnoses were found to be non-malignant, including upper gastrointestinal problems in men and urinary tract infections in women.

A study shows the Visceral Sensitivity Index could help identify anxiety and health-related quality of life burden in patients with IBS or IBD.